ERBB2 and gastric cancer: Drug sensitivity analysis revealed therapeutic strategies for different prognostic groups.The low-scoring group was more sensitive to first-line chemotherapeutic agents such as 5-fluorouracil, cisplatin, paclitaxel, oxaliplatin, and epirubicin (p<0.001) (52), as well as responded well to HER2/EGFR-targeted agents such as lapatinib and erlotinib, which was consistent with the results of clinical trials in HER2-positive or EGFR-highly-expressed gastric cancer (53, 54).